Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
u9KZyy4uLqhmzyz2
